Faculty profile

Curtis Cooper

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

Curtis Cooper

Associate Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
65 publications in the last five years, latest in 2026.
Senior (last) author on 13 recent papers, a sign of leading a research group.
Principal investigator on 20 research grants (20 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

182

Publications

1,243

Citations

h-index

222

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Knowledge Translation Hcv Hiv Continuing Education Responsive Programming Mentorship Virology Co-Infection

Latest papers

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.
Infectious diseases and therapy · 2026 · first author
Post-Traumatic Stress Symptoms Related to the COVID-19 Pandemic in Persons Living and Aging with HIV.
AIDS research and human retroviruses · 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIV.
Gastro hep advances · 2026

All 182 publications

Latest funding

Identifying CD8 T Cell Immunometabolic Scars in Chronic HCV and Metabolic Liver Disease and Their Impact on HCC Responses
CIHR · 2025 · Co-investigator
$1,296,676
Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada
CIHR · 2025 · Co-investigator
$2,999,998
Advancing Excellence: A Professional Development Workshop for Mid-Career Virologists
CIHR · 2024 · Nominated PI
$20,000

All 46 grants and awards

From the 150 most recent of 182 publications.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Cooper C, Raina SA, Johnson L, Feld JJ, Brown A, Martinez A, Conway B, Gordon SC, Asselah T, Uribe L, Li M, Iacob A, Marcinak J, Semizarov D, Pol S

Infectious diseases and therapy2026First author

DOI: 10.1007/s40121-026-01339-y PMID: 41951998

Post-Traumatic Stress Symptoms Related to the COVID-19 Pandemic in Persons Living and Aging with HIV.

Walmsley S, Mabipoor M, Wai A, Cooper C, Boyachuk B, Loutfy M, Klein M, CTN-COVID HIV Study Team

AIDS research and human retroviruses2026

DOI: 10.1177/08892229261472161 PMID: 42494072

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIV.

Cinque F, Nudo M, Saeed S, Lim J, Kablawi D, Mariano G, Lupu A, Elgretli W, Moodie EEM, Price C, Monteith K, Cooper C, Walmsley S, Kronfli N, Cox J, Costiniuk C, De Pokomandy A, Routy JP, Klein MB, Lebouche B, Sebastiani G

Gastro hep advances2026

DOI: 10.1016/j.gastha.2026.100966 PMID: 42181046

Optimal timing of infant post-vaccination serological testing for hepatitis B virus immunity.

Coffin CS, Fung S, Osiowy C, Alvarez F, Cooper C, Ko HH, Poulin S, van Gennip J

Canadian liver journal2026

DOI: 10.3138/canlivj-2025-0037 PMID: 42131699

Telemedicine and hybrid engagement models facilitate hepatitis C cascade of care during periods of healthcare disruption.

Fan S, Imsirovic H, Cooper C

Annals of hepatology2026Senior author

DOI: 10.1016/j.aohep.2025.102178 PMID: 41453643

Time to Hepatitis C Care Engagement and Treatment Outcomes in Canadian Immigrants Have Markedly Improved Over Three Decades.

Fan S, Imsirovic H, Garber G, Kelly E, Cooper C

Journal of viral hepatitis2026Senior author

DOI: 10.1111/jvh.70112 PMID: 41311292

Health care providers' perspectives on barriers and enablers to providing hepatitis C screening and treatment for immigrants in Canada: A theory-informed qualitative study.

Mortazhejri S, Greenaway C, Cooper C, Pakhale S, Presseau J, Grimshaw JM, Patey AM

Canadian liver journal2026

DOI: 10.3138/canlivj-2025-0045 PMID: 42404989

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Tremblay C, Valea I, Ndiaye BP, Barry H, ElSherif M, Cooper C, Breeze JL, Cai Y, Ye L, Omole T, Halperin SA, Mboup S, Langley JM

The lancet. HIV2026

DOI: 10.1016/s2352-3018(26)00118-9 PMID: 42567171

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Transplantation and Cellular Therapy20263 citations

DOI: 10.1016/j.jtct.2025.10.037

Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic

Shaver N, Colijn C, Heffernan J, Asamoah GD, Piggott T, Cooper C, Bagheri S, Crawley AM, Kagina BM, Bowdish DME

EBioMedicine20262 citations

DOI: 10.1016/j.ebiom.2026.106204

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Curtis Cooper

Research

Latest papers

Latest funding

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Post-Traumatic Stress Symptoms Related to the COVID-19 Pandemic in Persons Living and Aging with HIV.

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIV.

Optimal timing of infant post-vaccination serological testing for hepatitis B virus immunity.

Telemedicine and hybrid engagement models facilitate hepatitis C cascade of care during periods of healthcare disruption.

Time to Hepatitis C Care Engagement and Treatment Outcomes in Canadian Immigrants Have Markedly Improved Over Three Decades.

Health care providers' perspectives on barriers and enablers to providing hepatitis C screening and treatment for immigrants in Canada: A theory-informed qualitative study.

Safety and immunogenicity of one or two doses of the rVSV&#x394;G-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic

Frequent collaborators

Sharon Walmsley

Mark Hull

Sharon Walmsley

Shariq Haider

Mona Loutfy

Janet Raboud

John Gill

Curtis Cooper

Marek Smieja

Giada Sebastiani

Sahar Saeed

Sergio Borgia

Neora Pick

Tony Antoniou

Valérie Martel-Laferrière

Nadine Kronfli

Rolando Barrios

David Wong

Gary Garber

Mary Doyle

Julio Montaner

Edward Joseph Mills

Charles Harry Goldsmith

Marina Klein

Robert Hogg

Sharon Walmsley

Curtis Cooper

Robert Hogg

Julian Little

John Gill

Michael Sebag

Christos Tsoukas

Amaris Karin Balitsky

Claire Kendall

Dawn Bowdish

Angela Crawley

Keith Tsoi

Sean Rourke

Claire Kendall

Soo Ying Chan Carusone

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.